Plain-English translation of NCT06667700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help prevent severe COVID-19 illness in adults who are at high risk. works by stopping the COVID-19 virus from making copies of itself in your body. Researchers want to know if this treatment works better than a placebo (a pill with no medicine) in preventing serious illness.
While most people with COVID-19 get mild symptoms, some people are at higher risk of becoming very sick. Some of these people cannot take other available COVID treatments because of other medicines they take or health conditions they have. This trial is looking for another treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
If you qualify and join, you will be randomly assigned to receive either the study medication or a placebo. You will take a pill by mouth every 12 hours for 5 days (10 doses total). Researchers will track your symptoms and health over time to see whether the medication helps prevent you from getting severely ill. You may also receive other standard COVID-19 treatments like remdesivir if your doctor thinks you need it.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States